131 related articles for article (PubMed ID: 27433786)
1. Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.
Turner AR; Lane BR; Rogers D; Lipkus I; Weaver K; Danhauer SC; Zhang Z; Hsu FC; Noyes SL; Adams T; Toriello H; Monroe T; McKanna T; Young T; Rodarmer R; Kahnoski RJ; Tourojman M; Kader AK; Zheng SL; Baer W; Xu J
Cancer; 2016 Nov; 122(22):3564-3575. PubMed ID: 27433786
[TBL] [Abstract][Full Text] [Related]
2. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
[TBL] [Abstract][Full Text] [Related]
3. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
[TBL] [Abstract][Full Text] [Related]
4. Family history in the Finnish Prostate Cancer Screening Trial.
Saarimäki L; Tammela TL; Määttänen L; Taari K; Kujala PM; Raitanen J; Auvinen A
Int J Cancer; 2015 May; 136(9):2172-7. PubMed ID: 25274038
[TBL] [Abstract][Full Text] [Related]
5. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
[TBL] [Abstract][Full Text] [Related]
6. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
7. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Otto SJ; van der Cruijsen IW; Liem MK; Korfage IJ; Lous JJ; Schröder FH; de Koning HJ
Int J Cancer; 2003 Jun; 105(3):394-9. PubMed ID: 12704675
[TBL] [Abstract][Full Text] [Related]
8. Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study.
Kirkegaard P; Edwards A; Nielsen TLO; Ørntoft TF; Sørensen KD; Borre M; Bro F
BMC Fam Pract; 2018 Feb; 19(1):32. PubMed ID: 29454309
[TBL] [Abstract][Full Text] [Related]
9. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
Beemsterboer PM; de Koning HJ; Kranse R; Trienekens PH; van der Maas PJ; Schröder FH
J Urol; 2000 Oct; 164(4):1216-20. PubMed ID: 10992369
[TBL] [Abstract][Full Text] [Related]
12. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
14. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
15. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
Bunting PS; Goel V; Williams JI; Iscoe NA
CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
[TBL] [Abstract][Full Text] [Related]
17. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
